Form 8-K - Current report:
SEC Accession No. 0001628280-25-031818
Filing Date
2025-06-17
Accepted
2025-06-17 16:01:23
Documents
13
Period of Report
2025-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20250617.htm   iXBRL 8-K 44097
  Complete submission text file 0001628280-25-031818.txt   184860

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250617.xsd EX-101.SCH 2104
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20250617_def.xml EX-101.DEF 14550
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250617_lab.xml EX-101.LAB 24544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250617_pre.xml EX-101.PRE 15065
15 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250617_htm.xml XML 2629
Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 251053239
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)